Tag:

Genzyme

Latest Headlines

Latest Headlines

Sanofi nabs FDA approval for Kynamro, despite safety concerns

The FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY) Genzyme unit.

Amgen, Genzyme race to develop new manufacturing process

Manufacturing biotech drugs inside living cells is a complex and expensive task. But two big outfits, Amgen and Sanofi's Genzyme, are racing to develop a new process that promises to significantly reduce the cost of proteins and antibodies, according to a story in MIT's Technology Review.

Sanofi CEO uses Lemtrada's step forward to tout R&D future

Sanofi ($SNY) CEO Chris Viehbacher paid tribute to his Genzyme unit's MS drug candidate Lemtrada as the FDA accepted the company's application for its U.S. approval.

Amicus jumps on upbeat data for Pompe drug

Amicus Therapeutics revealed its success in a small midstage study of its drug to enhance enzyme therapy in patients with the rare genetic disorder Pompe disease. On the back of the upbeat data, the biotech company's shares recovered some of the lost ground from news last month of a Phase III failure for its lead candidate.

Ex-Genzyme CEO to serve as Prosensa's strategic adviser

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

EMA committee shoots down Sanofi's cholesterol drug mipomersen

A European Medicines Agency panel handed down a negative opinion late this week on the antisense drug from Isis Pharmaceuticals for treating a genetic disease that causes blood cholesterol to jump, citing safety concerns such as signs of liver toxicity and cardiovascular risks in patients in clinical trials.

Ex-Genzyme CEO Termeer returns to his roots at biotech Prosensa

The former Genzyme CEO and chairman has joined the biotech Prosensa as a strategic adviser, bringing his experience in building Genzyme into a world leader in rare diseases.

NanoString draws $15.3M Series E for cancer Dx test launch

NanoString Technologies attracted $15.3 million in Series E financing, which it will use to advance the commercial launch of its debut breast cancer assay, navigate the U.S. regulatory approval process for its test and further its overall pipeline.

Targacept taps Stephen A. Hill to serve as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Manufacturers return some drugs to market but shortages persist

There has been progress on the drug shortages front in the last few weeks with a couple of drugmakers saying manufacturing improvements have allowed them to again meet demand for two critical drugs. But as  The New York Times  points out, even with new drug shortages popping up at half the numbers of a year ago, there are still dozens of drugs in short supply.